fb-pixel Skip to main content

DEM BioPharma launches with $70m to take a bite out of cancer

The Cambridge startup is developing drugs that reveal malicious cells and allow the immune system to attack them.

Japanese drug giant Takeda will move into 16-story building planned for Kendall Square
The company says it wants to create a consolidated campus in Cambridge and is signing a 15-year lease on a planned 600,000 square-foot lab and office space at 585 Third St.

Startup Elucid hopes that AI can help cardiologists prevent heart attacks
The Boston firm raised $27 million for FDA-cleared software that reads scans and makes recommendations for preventative treatments.

Lexington-based startup will target cystic fibrosis with a new twist on gene therapy
Carbon Biosciences launched with $38 million to develop gene therapies based on parvoviruses, which it hopes will be safer and more effective than existing technologies.

FDA advisers offer a vote of confidence for gene therapies
An advisory panel of the US Food and Drug Administration voted this month to recommend two gene therapies from Cambridge-based Bluebird Bio, giving optimism to other companies that are developing similar gene therapies.

Third Rock raises $1.1 billion for its largest fund yet
The Boston venture capital firm plans to use the money to launch more biotechs, despite the sector’s recent downturn.

More Life Sciences Headlines

FDA advisers offer a vote of confidence for gene therapies

An advisory panel of the US Food and Drug Administration voted this month to recommend two gene therapies from Cambridge-based Bluebird Bio, giving optimism to other companies that are developing similar gene therapies.

Third Rock raises $1.1 billion for its largest fund yet

The Boston venture capital firm plans to use the money to launch more biotechs, despite the sector’s recent downturn.

FDA advisory committee unanimous in support of Bluebird Bio’s two gene therapies

It’s a much-needed win for the struggling Cambridge biotech but doesn’t guarantee approval.

Bluebird Bio nears moment of truth as FDA evaluates its gene therapies

The approval or rejection of Bluebird’s gene therapies will be a make-or-break moment for the struggling Cambridge biotech firm.

Omicron booster shots are taking longer than expected. Will the wait be worth it?

Pfizer once promised to make updated COVID shots in 100 days. More than 200 days will have elapsed by the time the FDA meets to discuss plans for those boosters in late June.

Upstream Bio raises $200 million to develop treatment for severe asthma

The Waltham startup acquired the experimental antibody therapy from Japanese drug maker Astellas.

GSK to buy Cambridge vaccine startup Affinivax for $2.1b, with more payments possible

The local biotech is developing a shot that protects against 24 types of pneumococcal bacteria.

Flagship’s latest startup launches with bold claim: the discovery of thousands of new human proteins

The venture capital giant has committed $75 million to Cambridge biotech ProFound Therapeutics.